| INTRODUCTION
In the past decade, treatment of hepatitis C infection with different combinations of direct-acting antiviral agents (DAAs) has been revolutionized. The most recent advances in this field have led to 8-to 12 week-long treatments with a single-pill all-oral pan-genotypic regimens with over 95% sustained virologic response (SVR) rates. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In fact, these high rates of response have been documented even in difficult-to-treat HCV subpopulations, including those with genotype 3, cirrhosis, and prior DAA experience. 2, 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, the regimens have been shown to be simple, safe, and also associated with improved patient-reported outcomes (PROs) such as health-related quality of life (HRQL), fatigue, and daily functioning during and after treatment. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] A relatively new addition to the landscape, 8-or 12 week-long regimens containing sofosbuvir (SOF), velpatasvir (VEL) and voxilaprevir (VOX) has been shown to result in excellent efficacy and safety. 1, 16 Prior studies reported significant improvements in multiple aspects of patients' well-being in different patient populations treated with SOF/VEL alone. [29] [30] [31] [32] [33] However, the effect of the addition of VOX, a pan-genotypic NS3/4A protease inhibitor, on on-treatment and post-treatment PROs is not well understood. Therefore, the aim of the current study was to assess treatment-emergent changes in
PROs of DAA-na€ ıve patients with chronic HCV who received the new SOF/VEL/VOX regimen and to compare those to PROs of patients who received SOF/VEL only.
| ME TH ODS
In this study, we used the PRO data collected from participants of POLARIS-2 (clinicaltrials.gov #NCT02607800) and POLARIS-3 (#NCT02639338) studies; both studies were randomized open-label phase 3 clinical trials of SOF/VEL/VOX in DAA-na€ ıve (treatmentna€ ıve or treatment-experienced with an IFN-based regimen) patients with chronic HCV infection. In POLARIS-2, DAA-na€ ıve patients of all HCV genotypes with or without cirrhosis (excluding patients with genotype 3 and cirrhosis) were randomized 1:1, stratified by HCV genotype, cirrhosis status, and treatment history, to receive either a fixed-dose combination of SOF, VEL, and VOX (400/100/100 mg) once daily for 8 weeks or SOF/VEL (400/100 mg) once daily for 12 weeks. In POLARIS-3, DAA-na€ ıve patients with HCV genotype 3 and cirrhosis were also randomized 1:1 to receive these regimens, stratified by treatment history. In both studies, eligibility criteria included being of at least 18 years of age, willingness and ability to
give an informed consent, having no clinically significant illness or health condition other than chronic HCV infection, no history of hepatic decompensation, the absence of HBV or HIV co-infection, no recent alcohol or drug abuse, and no history of noncompliance during previous treatment with an IFN-based regimen, if any. 1, 16 In both studies, the presence of cirrhosis in participants was ascertained by a prior liver biopsy (Metavir score = 4), or a combination of APRI (>2) and Fibrotest (>0.75), or by transient elastography (>12.5 kPa).
The trials were conducted in the U.S., Canada, Australia, New Zealand, Germany, France, and the United Kingdom in 2015-2017. 40 Thus, the four PRO instruments assess a total of 25 PRO domain and summary scores. In addition,
we also used SF-36 to calculate the preference-based utility score (SF-6D) using a previously published non-parametric algorithm. 41 The use of these four PRO instruments in clinical trials in patients with HCV has been previously described. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] With the exception of WPAI:SHP, all instruments presume positive scoring of the included PROs (ie, greater scores are supposed to reflect better health status).
For presentation purposes, we additionally transformed changes in
PROs from their original scales to a universal 0-100 scale.
| Statistical analysis
Clinico-demographic parameters, baseline, on-treatment, and posttreatment PRO scores were summarized as N (%) or mean AE standard deviation and compared between the two treatment arms using chi-square test or a Mann-Whitney non-parametric test. Also, at all study time points, we calculated the changes (decrements or improvements) in the PRO scores with reference to patients' own baseline levels, and used Wilcoxon sign rank test to identify significant changes. Only P-values not exceeding 0.05 were considered potentially statistically significant.
Independent predictors of PRO scores at baseline, during treatment and in follow-up were assessed using multiple linear regression models. Potential predictors included location (USA vs non-USA), age, gender, race, BMI, anti-HCV treatment history, history of psychiatric comorbidities, clinically overt fatigue, the presence of type 2 diabetes, and the presence of cirrhosis; these potential predictors were subjected to bidirectional stepwise selection with P = .20 for entry and 0.05 for stay. At post-baseline time points, we also assessed the association of the treatment regimen used with the treatment-emergent changes in the PRO scores; for that purpose, adjustment for the baseline PRO levels was added.
All analyses were run using SAS 9.4 (SAS Institute, Cary, NC). 
| RESULTS
A total of 1160 DAA-naive patients with chronic HCV were included. Of these, 549 were treated with SOF/VEL and 611 with SOF/VEL/VOX. The cohort from the two studies was 52.8 AE 11.0 years old, 56% male, 82% white, 56% enrolled in the U.S., 75% treatment-na€ ıve, and 34% cirrhotic. Clinico-demographic parameters of patients assigned to different treatment regimens were generally similar except for a slightly greater proportion of Asian patients in the SOF/VEL/VOX group and genotype imbalance as per the design of the original studies ( Table 1, Table S1 ). Consistent with prior reports, during treatment, there was a higher rate of mild gastrointestinal adverse events in the SOF/VEL/VOX group:
29.6% vs 14.8% (P < .0001). The SVR-12 rates were 95%-98% in both treatment arms in the two studies. 
| Patient-reported outcomes during treatment
Regardless of the regimen, significant improvements in nearly all studied PRO scores were observed soon after treatment initiation. In particular, by treatment week 4, improvements from the baseline scores were statistically significant in both treatment arms for 20 out of the 26 PRO domains, and the average magnitude of such improvement ranged from +1.7 to +12.5 points on a universal 0-100 PRO scale (Figure 1A) . The same or greater improvements were sustained throughout treatment duration. With reference to patients' own baseline levels, the PRO scores improved in 22/26 domains in both treatment arms, and the average improvement ranged from +2.3 to +15.0 points ( Figure 1B ). No differences in treatment-emergent changes in the PRO scores were seen between SOF/VEL and SOF/VEL/VOX treatment arms at any time point during treatment (all P > .05).
In a subgroup analysis of patients with cirrhosis (N = 193 treated with SOF/VEL, N = 200 with SOF/VEL/VOX), PRO improvements were equivalent or more pronounced in those with cirrhosis as compared to those without cirrhosis: from +2.7 to +17.9 points by the end of treatment (P < .05) (Figure 2 ).
| Patient-reported outcomes after treatment
After treatment cessation, regardless of the regimen, all PRO gains were sustained or further improved (Figure 3 ). In particular, by posttreatment week 4, all but one PRO improvement became statistically significant, and the average PRO improvement ranged from +2.6 to +16.4 points. By post-treatment week 12, the same improvements were noted ranging from +2.7 to +16.7 points ( Figure S1A ). Finally, by post-treatment week 24, these PRO gains increased ranging from +3.9 to +20.1 points ( Figure S1B ). In fact, by week 24 follow-up, the only PRO domain that did not improve was the Absenteeism component of WPAI:SHP which remained at the baseline level at all time points (all P > .05).
In patients with cirrhosis, post-treatment PRO improvements were again similar or more pronounced in comparison to those without cirrhosis, ranging from +4.5 to +18.7 points by post-treatment week 12, from +4.4 to +23.5 points by post-treatment week 24.
| Predictors of patient-reported outcomes
In multivariate analysis, independent predictors of lower baseline PRO scores included older age, female gender, being enrolled outside the U.S., as well as history of anxiety, depression, clinically overt fatigue, sleep disorders, cirrhosis, and DM (Table S2) . After additional adjustment for the baseline PRO levels, no association of the treatment regimen used (SOF/VEL vs SOF/VEL/VOX) with on-treatment or post-treatment PRO scores was found (all P > .05). On the other hand, having baseline comorbidities or cirrhosis was associated with greater PRO improvements during or after treatment (Table S3) .
In a separate multivariate analysis of patients with cirrhosis, independent predictors of lower PROs included history of depression, anxiety, and insomnia. Similarly, to the entire cohort, no association of the treatment regimen with treatment-emergent PROs (after adjustment for the baseline levels) was found (all P > .05).
| DISCUSSION
In this study, we have shown that treatment of chronic hepatitis C with SOF/VEL/VOX, a new pan-genotypic regimen, positively impacts patients' experience during treatment and after achieving SVR. These data support the comprehensive benefit of this regimen for patients with chronic HCV infection. Furthermore, it is important to note that the PRO improvements which were seen early after the initiation of treatment, coincided with early virologic response, and became more prominent by the end-of-treatment. Additionally, it is also important to note that most improvements in PRO scores were not only statistically significant but also clinically relevant meeting the threshold for the minimal clinically important difference (MCID) in PRO scores. 45 Nevertheless, our data shows that the increased rate of gastrointestinal side effects in the SOF/VEL/VOX group did not significantly impact PROs (all P > .05 at the end of treatment).
Consistent with prior reports, independent predictors of lower baseline PRO scores in this study were primarily related to the presence of co-morbidities such as anxiety, depression and clinically overt fatigue. At the same time, patients with comorbidities also enjoyed the greatest improvement of their PROs after clearance of their HCV infection. Furthermore, the PRO improvements in patients with cirrhosis were even more prominent in comparison to the score changes seen in non-cirrhotic patients. This suggests that observed PRO improvements may be partially related to viral suppression and/or viral eradication, which is seen in all patients, but also may be related to improvement in liver function which would primarily manifest in patients with cirrhosis and extrahepatic manifestations of HCV infection. This is especially important since patients with HCV and cirrhosis are not only at the highest risk for developing adverse clinical outcomes but also experience severe impairment of their PROs.
The study limitations include the clinical trial-related selection bias in the study cohort, the open label design, differing study durations for the studied regimens, and a relatively short follow-up duration. Nevertheless, duration of treatment with interferon and ribavirin free regimens does not seem to impact PROs. [29] [30] [31] [32] [33] Despite these limitations, the strengths of the study include a large, multinational, and prospectively followed cohort of patients with HCV, and the use of four fully validated instruments to assess a number of different PRO domains which cover multiple aspects of patients' wellbeing. Indeed, the observed synchronous improvement of PROs in 25 out of 26 studied domains (absenteeism was the only domain not to improve, possibly due to a relatively short follow up; studies are Nevertheless, to establish generalizability, the findings need to be further validated in a real-life setting with more diverse patient populations. This is especially important since being from outside the United States was a predictor for lower PRO scores at baseline and of some treatment-emergent changes in PROs. In this context, studies are needed to understand the drivers of these cultural differences. However, we must emphasize that, regardless of these differences, patients who achieved SVR saw a significant increase in their PROs which also exceeded the minimal clinically importance difference. We would also suggest that adding qualitative data to assessing PROs should be considered given the considerable favor- In summary, these data show that the new pan-genotypic regimens of SOF/VEL/VOX or SOF/VEL are not only associated with high efficacy but also with substantial improvement in PRO scores.
These improvements were seen across regimens and genotypes and were more prominent in patients with cirrhosis and other comorbidities. In this context, the comprehensive benefit of these regimens includes not only high SVR rates but also improvement of patients' experience during treatment and after achieving SVR.
